Key result
Biochemical recovery after GDMT optimization was independently associated with a lower risk of HF events, whereas LVEF recovery lost significance.
Why the study?
Reverse remodelling in HFrEF involves biochemical and structural improvements, but their relative and independent prognostic roles remain unclear.
Does biochemical or structural recovery better predict 3-year HF event-free survival in HFrEF patients after GDMT optimization?
Cohort (n=270)
Does biochemical or structural recovery better predict 3-year HF event-free survival in HFrEF patients after GDMT optimization?
Biochemical reverse remodelling (NT-proBNP reduction) is an independent predictor of outcomes in HFrEF after GDMT optimization, providing incremental prognostic information beyond LVEF recovery.
Answers are grounded in this paper and cite their sources.
Biochemical vs structural recovery may carry distinct prognostic weight in HFrEF on GDMT; leaves open which should guide therapy or trial endpoints.
Abstract Introduction and Aim Reverse remodelling in HFrEF involves both biochemical improvements, reflecting neuro-hormonal inhibition, and structural changes in ventricular function, yet their relative and independent prognostic roles are unclear. This study evaluated baseline characteristics across recovery phenotypes during medical therapy (GDMT) optimization and assessed the prognostic impact of biochemical versus structural recovery. Methods We retrospectively analyzed 270 HFrEF patients followed for 3 years after GDMT optimization. Patients were categorized into three mutually exclusive groups according to predefined criteria: biochemical recovery only (≥50% NT-proBNP reduction and follow-up NT-proBNP <1000 pg/mL, without LVEF improvement), LVEF recovery (>10% absolute increase and follow-up LVEF >40%, irrespective of NT-proBNP changes) and no recovery (neither criterion fulfilled). Baseline characteristics were compared using ANOVA or χ² tests. Kaplan–Meier curves assessed 3-year HF event-free survival. Prognostic effects were quantified using univariable and multivariable Cox regression, and incremental value was evaluated by changes in chi-square model. Results Baseline characteristics were similar across groups. Only sex distribution and eGFR differed between groups. Three-year event-free survival varied markedly across phenotypes (log-rank p<0.001). In univariable Cox regression, LVEF recovery was associated with a significantly lower risk of HF events (HR 0.288, 95% CI 0.154–0.538; p<0.001), and biochemical recovery conferred a similarly strong protective effect (HR 0.244, 95% CI 0.112–0.532; p<0.001). When both domains were included simultaneously, biochemical recovery remained independently associated with prognosis (HR 0.309, 95% CI 0.145–0.659; p=0.002), whereas LVEF recovery lost significance (HR 0.437, 95% CI 0.190–1.008; p=0.052). Biochemical recovery provided significant incremental prognostic information beyond LVEF recovery (Δχ²=22.4; p<0.001), whereas LVEF recovery added no meaningful improvement over biochemical recovery (Δχ²=3.77; p=0.052). Conclusions Biochemical reverse remodelling emerged as the only independent predictor of outcomes. Interestingly, these findings indicate that neuro-hormonal inhibition, and maybe, appropriate decongestion— captured biochemically — is the primary driver of prognostic benefit after GDMT optimization, whereas structural recovery appears later and may be partially mediated by upstream neuro-hormonal improvement.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) conducted a cohort in Heart Failure with reduced Ejection Fraction (HFrEF) (n=270). Biochemical recovery vs. No recovery / LVEF recovery was evaluated on Heart failure events (HR 0.309, 95% CI 0.145-0.659, p=0.002). Biochemical recovery after GDMT optimization was independently associated with a lower risk of HF events, whereas LVEF recovery lost significance.
Synapse has enriched 10 related papers. Consider them for comparative context: